4.4 Article

Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements

期刊

BMC NEUROLOGY
卷 21, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12883-021-02450-y

关键词

Perampanel; Epilepsy; Delphi procedure; Antiepileptic drugs; Adjunctive therapy

向作者/读者索取更多资源

Consensus was reached on the suitability of Perampanel as a first add-on based on its positive impact on quality of life, efficacy, tolerability, ease of use, and unique mechanism of action. However, potential unfavorable factors include slow dose titration, behavioral adverse effects, lack of safety information during pregnancy, and limited access to plasma Perampanel levels.
Background When use of a single antiseizure medication (ASM) fails to induce seizure remission, add-on therapy is justified. Perampanel (PER) is approved in Europe as adjunctive therapy for focal, focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures. Aim of the study was to establish whether PER is suitable for first add-on use. Methods A Delphi methodology was adopted to assess consensus on a list of 39 statements produced by an Expert Board of 5 epileptologists. Using an iterative process, statements were finalized by a Delphi Panel of 84 Italian pediatric and adult neurologists. Each statement was rated anonymously to determine level of agreement on a 9-point Likert scale. Consensus was established as agreement by at least 80% of the panelists. The relevance of each statement was also assessed on a 3-point scale. Results Consensus was achieved for 37 statements. Characteristics of PER considered to justify its use as first add-on include evidence of a positive impact on quality of life based on long term retention data, efficacy, tolerability, and ease of use; no worsening of cognitive functions and sleep quality; a low potential for drug interactions; a unique mechanism of action. Potential unfavorable factors are the need for a relatively slow dose titration; the potential occurrence of behavioral adverse effects; lack of information on safety when used in pregnancy; limited access to plasma PER levels. Conclusion Perampanel has many features which justify its use as a first add-on. Choice of an ASM as first add-on should be tailored to individual characteristics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据